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MC903 (calcipotriol) is a synthetic, low calcemic
analog of the nuclear hormone 1a,25-dihydroxyvita-
min D3 and used in the treatment of psoriasis. The
bene®cial effects of MC903 on psoriasis are based on
gene regulatory events. The genomic actions of
1a,25-dihydroxyvitamin D3 and its analogs are pri-
marily mediated by a complex of the vitamin D3
receptor and the retinoid X receptor bound to a
1a,25-dihydroxyvitamin D3 response element that
can be considered as the molecular switch of 1a,25-
dihydroxyvitamin D3 signaling. In this study, the
interaction of MC903 and two new analogs, GS1500
and EB1213, with this molecular switch was com-
pared with that of 1a,25-dihydroxyvitamin D3. In
DNA-dependent limited protease digestion assays,
ligand-dependent gel shift assays and mammalian-
one-hybrid assays, all four ligands appeared to be
equally sensitive VDR agonists that activated vitamin
D3 receptor±retinoid X receptor±1a,25-dihydroxyvi-
tamin D3 response element complexes at a concen-
tration of approximately 0.2 nM. The analyzed VDR
agonists, however, also showed individual molecular
properties, such as a reduced sensitivity in HaCaT
cells (MC903), a selectivity for DNA-bound vitamin
D3 receptor±retinoid X receptor heterodimers
(GS1500) and a long-lasting stabilization of vitamin
D3 receptor±retinoid X receptor±1a,25-dihydroxyvi-
tamin D3 response element complexes (EB1213).
This molecular evaluation demonstrated that the sen-
sitivity in activating the vitamin D3 receptor is
already optimal for MC903, but the analog may not
be ideal in keeping the receptor active and in select-
ively triggering 1a,25-dihydroxyvitamin D3 signaling
pathways. Key words: gene regulation/receptor conform-
ation/vitamin D analogs/vitamin D receptor. J Invest
Dermatol 116:785±792, 2001
T
he nuclear hormone 1a,25-dihydroxyvitamin D3
(1a,25(OH)2D3) is involved in the regulation of a
variety of important biologic functions, such as
calcium homeostasis (Mùrk Hansen et al, 1996), as
well as cellular growth, differentiation and apoptosis
(Walters, 1992). These properties provide 1a,25(OH)2D3 with an
interesting therapeutic potential against a variety of diseases, such as
osteoporosis, cancer, and psoriasis (Pols et al, 1994). A more
selective biologic pro®le of the hormone would be desired,
however, as at superphysiologic (i.e., pharmacologic) concentra-
tions the calcemic function of the hormone can cause side-effects,
such as hypercalcemia, hypercalciuria, and soft tissue calci®cation
(Vieth, 1990). Therefore, more than 2000 analogs of
1a,25(OH)2D3, which mainly contain modi®cations of the side
chain, have been developed with the goal of improving the
biologic pro®le of the natural hormone for a potential therapeutic
application (Bouillon et al, 1995); however, only very few of these
analogs have been chosen for clinical trials. Presently, the clinically
most successful 1a,25(OH)2D3 analog, MC903 (calcipotriol), is
topically applied against keratinocyte dysfunction in psoriasis.
MC903 is a very low calcemic analog, mainly because systemically
it is clearly more rapidly metabolized than the natural hormone
(Kissmeyer and Binderup, 1991). Therefore, MC903 is active in
keratinocytes and other dermal cells (Masuda et al, 1994), but has
only very minor systemic effects; however, MC903 is still not a
perfect drug, as it is not effective in all psoriasis patients and it may
cause skin irritations in some. This leads to the question, if other
analogs are more potent and selective in their action than MC903.
A very helpful and desired prerequisite to the rational design of
1a,25(OH)2D3 analogs is the detailed understanding of their
molecular action. 1a,25(OH)2D3 and its analogs are speci®c ligands
to the vitamin D3 receptor (VDR) (Pike, 1991) that is a member of
the nuclear receptor transcription factor superfamily (Mangelsdorf
et al, 1995). The VDR acts preferentially as a heterodimer with the
retinoid X receptor (RXR) (Carlberg, 1996) on speci®c DNA
sequences in promoter regions of 1a,25(OH)2D3 target genes,
referred to as 1a,25(OH)2D3 response elements (VDRE)
(Carlberg, 1995). Simple VDRE are formed by two hexameric
binding sites and VDR-RXR heterodimers bind preferentially to
directly repeated binding site arrangements with three intervening
nucleotides (DR3-type VDRE) or to inverted palindromes spaced
by nine nucleotides (IP9-type VDRE). In addition, VDRE formed
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by direct repeats with by four or six intervening nucleotides have
been described (Carlberg, 1997). Like all members of the nuclear
receptor superfamily, the VDR contains a characteristic DNA-
binding domain (DBD), that is formed by two zinc-®nger motifs
(Glass, 1994), and a ligand-binding domain (LBD) that consists of
12 a-helices (Moras and Gronemeyer, 1998). The most critical step
in 1a,25(OH)2D3 signaling is the induction of a conformational
change within the LBD of the VDR by interaction with
1a,25(OH)2D3 or its analogs. The three-dimensional structure of
the seven presently analyzed, ligand-bound LBD (including that of
the VDR; Rochel et al, 2000) suggested that there is a conserved
agonistic conformation of all nuclear receptor LBD. In this
agonistic conformation the activation function (AF) 2 domain
within helix 12 is able to contact the interaction domain of
coactivator proteins of the p160-family, such as SRC-1, TIF2, and
RAC3 (Herdick et al, 2000a), and/or of the DRIP/TRAP family
(Rachez et al, 1999).
In the last few years several in vitro and cell culture methods have
been developed that can be used for a molecular evaluation of the
ef®cacy of the VDR±ligand interaction. One of the most powerful
methods is the limited protease digestion assay, in which interaction
of the VDR with a ligand protects its LBD against protease
digestion, which allows a characterization and quantitation of
functional VDR conformations (Nayeri and Carlberg, 1997;
Quack and Carlberg, 2000a). Recently, it was shown that this
assay can also be performed in the presence of DNA and cofactors
(Herdick et al, 2000a; Quack and Carlberg, 2000a). The ligand-
dependent gel shift assay provides a quantitation of the ligand-
dependent VDR-RXR-VDRE complex formation and monitors
receptor dimerization, DNA binding, and ligand interaction at the
same time (Quack et al, 1998; Quack and Carlberg, 2000b). The
mammalian-one-hybrid assay is a most simpli®ed version of a
reporter gene assay, in which the functionality of the isolated
VDR-LBD can be monitored in different living cells (Herdick et al,
2000a). The three methods together provide suf®cient informations
for a molecular evaluation of a VDR ligand. In this report, the
three assays systems were used for the evaluation of MC903 in
comparison with two new analogs, GS1500 and EB1213, and the
natural hormone. All four ligands appeared to be equally sensitive
VDR agonists, but also showed individual molecular properties,
such as a reduced sensitivity in HaCaT cells (MC903), a selectivity
for DNA-bound VDR-RXR heterodimers (GS1500), and a long-
lasting stabilization of VDR-RXR-VDRE complexes (EB1213).
MATERIALS AND METHODS
Compounds 1a,25(OH)2D3 and its analogs MC903 (Carlberg
et al, 1994), GS1500 (Mathiasen et al, 1998), and EB1213 (Mùrk
Hansen et al, 1996) (for the structure of their side chains see Fig 1)
were synthesized in the Department of Chemical Research at LEO
Pharmaceutical Products (Ballerup, Denmark). Most characteristic
are the cyclopropane ring in MC903 and the aromatic benzene ring
in GS1500 and EB1213 combined with an altered stereochemistry
at the C20 atom (20-epi). All VDR agonists were dissolved in
2-propanol; further dilutions were made in dimethyl sulfoxide (for
in vitro experiments) or in ethanol (for cell culture experiments).
DNA constructs and in vitro protein translation The full-
length cDNA for human VDR (Carlberg et al, 1993) and human
RXRa (Levin et al, 1992) were subcloned into the SV40
promoter-driven pSG5 expression vector (Stratagene, Heidelberg,
Germany). In vitro translated VDR and RXR proteins were
generated by transcribing their respective linearized pSG5-based
cDNA expression vector with T7 RNA polymerase and translating
these RNA in vitro using rabbit reticulocyte lysate as recommended
by the supplier (Promega, Mannheim, Germany). For mammalian-
one-hybrid assays, the DBD of the yeast transcription factor GAL4
(amino acids 1±147) was fused with the cDNA of the human VDR
LBD (amino acids 109±427). In reporter gene constructs the
luciferase gene was driven either by three copies of the GAL4
binding site or four copies of the DR3-type VDRE of the rat ANF
gene promoter (core sequence AGAGGTCATGAAGGACA)
(Kahlen and Carlberg, 1996).
Limited protease digestion assay In vitro translated, [35S]-
labeled VDR protein alone or in combination with in vitro
translated RXR and 1 ng of unlabeled rat ANF DR3-type VDRE
were incubated with graded or saturating concentrations of ligand
for 15 min at room temperature in 20 ml binding buffer [10 mM
HEPES, pH 7.9, 1 mM DTT, 0.2 mg per ml poly(dI-C) and 5%
glycerol]. The buffer was adjusted to 150 mM of monovalent
cations by addition of KCl. Trypsin (Promega, ®nal concentration
8.3±16.6 ng per ml) was then added and the mixtures were further
incubated for 15 min (or indicated times, see Fig 4) at room
temperature. The digestion reactions were stopped by adding 25 ml
protein gel loading buffer (0.25 M Tris, pH 6.8, 20% glycerol, 5%
mercaptoethanol, 2% sodium dodecyl sulfate, 0.025%
bromophenol blue). The samples were denatured at 85°C for
3 min and electrophoresed through a 15% sodium dodecyl sulfate±
polyacrylamide gel. The gels were dried and exposed to a Fuji
MP2040S imager screen. The individual protease-sensitive VDR
fragments were quantitated on a Fuji FLA2000 reader (Tokyo,
Japan) using Image Gauge software.
Gel shift assay In vitro translated VDR-RXR heterodimers were
incubated with graded or saturating concentrations of ligands for
15 min at room temperature in a total volume of 20 ml binding
buffer. The buffer had been adjusted to 150 mM by addition of
KCl. Approximately 1 ng of the [32P]-labeled rat ANF DR3-type
VDRE (50,000 cpm) was added to the protein±ligand mixture and
incubation was continued for 20 min. Protein±DNA complexes
were resolved through 8% nondenaturing polyacrylamide gels in
0.5 3 TBE (45 mM Tris, 45 mM boric acid, 1 mM
ethylenediamine tetraacetic acid, pH 8.3) and were quantitated
on a Fuji FLA2000 reader.
Transient transfections and reporter gene assay HeLa
human cervix carcinoma cells and HaCaT immortalized human
Figure 1. Structure of 1a,25(OH)2D3 and its analogs. The structure
of the side chain is given.
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Figure 2. Stabilization of VDR conformations by 1a,25(OH)2D3 and its analogs. Limited protease digestion assays were performed by
preincubating in vitro translated [35S]-labeled VDR alone (A) or in combination with nonlabeled in vitro translated RXR and the rat ANF DR3-type
VDRE (B) with graded concentrations of 1a,25(OH)2D3 or its analogs. After digestion with trypsin, samples were electrophoresed through 15%
sodium dodecyl sulfate±polyacrylamide gels. The amount of ligand-stabilized VDR conformations 1 (c1LPD, ®lled circles) and 3 (c3LPD, open circles) in
relation to VDR input was quantitated by phosphorimaging. Representative experiments are shown for 1a,25(OH)2D3. Data points represent the mean
of triplicates and the bars indicate SD. The EC50 values for the stabilization of c1LPD were determined from the respective dose±response curves.
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keratinocytes were seeded on to six-well plates (105 cells per ml)
and grown overnight in phenol red-free Dulbecco's minimal
Eagle's medium supplemented with 10% charcoal-treated fetal
bovine serum. Liposomes were formed by incubating 1 mg of a
GAL4 binding site-driven luciferase reporter gene construct and
1 mg of an expression vector for a GAL4DBDVDRLBD-fusion
protein (for mammalian-one-hybrid assays in both cell lines) or
1 mg of the rat ANF DR3-type VDRE-driven reporter plasmid
and 1 mg each of pSG5-based receptor expression vectors for VDR
and RXR (for HaCaT cells) with 15±20 mg N-[1-(2,3-
Dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl sulfate
(DOTAP, Roth, Karlsruhe, Germany) for 15 min at room
temperature in a total volume of 100 ml. After dilution with
900 ml phenol red-free Dulbecco's minimal Eagle's medium, the
liposomes were added to the cells. Phenol red-free Dulbecco's
minimal Eagle's medium supplemented with 30% charcoal-treated
fetal bovine serum (500 ml) was added 4 h after transfection. At this
time, graded concentrations of VDR agonists were also added. The
cells were lyzed 16 h after onset of stimulation using the reporter
gene lysis buffer (Roche Diagnostics, Mannheim, Germany) for
both types of assays and the constant light signal luciferase reporter
gene assay was performed as recommended by the supplier
(Canberra-Packard, Dreieich, Germany). The luciferase activities
were normalized to protein concentration and induction factors
were calculated as the ratio of luciferase activity of ligand-
stimulated cells to that of solvent controls.
RESULTS
Stabilization of VDR conformation The interaction of
1a,25(OH)2D3 and its analogs MC903, GS1500, and EB1213
(for structure of their side chain see Fig 1) with the VDR in
solution (Fig 2A) or within VDR-RXR-VDRE complexes
(Fig 2B) was analyzed in DNA-independent and DNA-
dependent limited protease digestion assays, which were
performed with in vitro translated, [35S]-labeled VDR protein
alone or in combination with in vitro translated unlabeled RXR and
unlabeled rat ANF DR3-type VDRE, respectively. This assay
displays a concentration-dependent stabilization of two VDR
fragments, c1LPD (28 kDa) and c3LPD (23 kDa), that contain major
parts of the LBD [from the trypsin cutting site after arginine 173 to
either the carboxy-terminus at position 427 (c1LPD) or to arginine
391 (c3LPD)] and represent the agonistic and the nonagonistic
conformation of the VDR-LBD (Herdick et al, 2000a; Herdick and
Carlberg, 2000), whereas a reasonable amount of the VDR
fragment c2LPD is observed only with VDR antagonists (Bury et
al, 2000; Herdick et al, 2000b). All four ligands showed the typical
pro®le of VDR agonists, i.e., a stabilization of 60±80% of all VDR
molecules in c1LPD and only 10±20% in c3LPD (Herdick et al,
2000a). MC903 and EB1213 appeared to be indistinguishable from
the natural hormone as they stabilized VDR in solution with an
EC50 value of 1.2±1.5 nM, which is approximately ®ve times
higher than the concentration needed for a stabilization of the
VDR within VDR-RXR-VDRE complexes (EC50 value of 0.2±
0.3 nM). Interestingly, GS1500 showed the same sensitivity for the
stabilization of the VDR within VDR-RXR-VDRE complexes
Figure 3. 1a,25(OH)2D3 and its analogs stabilize VDR-RXR
heterodimer complex formation on DNA. Gel shift experiments
were performed with in vitro translated VDR-RXR heterodimers, which
were preincubated at room temperature with graded concentrations of
1a,25(OH)2D3 or its analogs and the [32P]-labeled rat ANF DR3-type
VDRE. Protein±DNA complexes were separated from free probe
through 8% nondenaturing polyacrylamide gels. The amount of VDR-
RXR-VDRE complexes in relation to free probe was quantitated by
phosphorimaging. A representative experiment is shown for
1a,25(OH)2D3. Data points represent the mean of triplicates and the bars
indicate SD. The EC50 values for VDR-RXR-VDRE complex
formation were determined from the respective dose±response curves.
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than the three other VDR agonists (EC50 value of 0.2 nM), but 50
times higher concentrations (EC50 value of 10 nM) were needed to
stabilize the VDR in solution.
Stabilization of VDR-RXR-VDRE complexes In order to
con®rm the DNA-dependent sensitivity of the four VDR agonists,
ligand-dependent gel shift assays were performed with in vitro
translated VDR-RXR heterodimers bound to the rat ANF DR3-
type VDRE and graded concentrations of 1a,25(OH)2D3 and its
three analogs (Fig 3). A comparable amount (approximately 20%
shifted probe) of concentration-dependent VDR-RXR
heterodimer complex formation on the VDRE was observed
with all four compounds and provided EC50 values between 0.095
and 0.4 nM. This ligand sensitivity is comparable with that
observed in DNA-dependent limited protease digestion assays
(Fig 2B). Moreover, this con®rms that all three analogs show a
sensitivity for the stabilization of VDR-RXR-VDRE complexes
that is very close to that of 1a,25(OH)2D3.
The kinetics of VDR-ligand dissociation within VDR-RXR-
VDRE complexes was analyzed by DNA-dependent limited
protease digestion assays, which were performed with in vitro
translated VDR-RXR heterodimers bound to the rat ANF DR3-
type VDRE and saturating concentrations of 1a,25(OH)2D3 and
the three analogs and solvent as a control (Fig 4). The incubation
time with trypsin varied between 15 min and 24 h. It is important
to note that trypsin was found to be still active even after 24 h of
incubation (data not shown). The amount of ligand-stabilized
VDR was quantitated and plotted over time, which allowed a
Figure 4. Different half-lives of VDR-ligand conformations.
Limited protease digestion assays were performed by preincubating in vitro
translated [35S]-labeled VDR together with nonlabeled in vitro translated
RXR and the rat ANF DR3-type VDRE and saturating concentrations
(10 mM) of 1a,25(OH)2D3, its analogs or solvent (as a control). The
samples were incubated for indicated times with trypsin and were then
electrophoresed through 15% sodium dodecyl sulfate±polyacrylamide
gels. The amount of ligand-stabilized VDR conformations (sum of c1LPD
and c3LPD) in relation to VDR input was quantitated by
phosphorimaging. Representative experiments are shown for all four
VDR agonists and solvent control. Data points represent the mean of
triplicates and the bars indicate SD. The half-lives (t1/2) were determined
from the respective time-course curves.
Figure 5. Agonistic effects of 1a,25(OH)2D3 and its analogs in vivo.
Luciferase reporter gene assays were performed with extracts from HeLa
cells that were transiently transfected with a reporter gene construct-
driven by three copies of the GAL4 binding site and an expression
vector for a GAL4DBDVDRLBD fusion protein (as schematically depicted
above). The cells were treated for 16 h with graded concentrations of
1a,25(OH)2D3 or its analogs. Stimulation of luciferase activity was
calculated in comparison with solvent-induced controls. Data points
represent the mean of triplicates and the bars indicate SD. The EC50
values for stimulation of VDR-driven gene activity were determined
from the respective dose±response curves.
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determination of the half-life (t1/2) of the VDR±ligand complex.
Interestingly, the three analogs showed clearly different t1/2 values,
which were found to be lower (MC903, t1/2 = 438 min) and
higher (GS1500, t1/2 = 1175 min and EB1213, t1/2 = 2717 min)
than that of the natural hormone (t1/2 = 660 min). If only the
stabilization of c1LPD is determined, the respective t1/2 values are
472, 260, 1260, and 3375 min for 1a,25(OH)2D3, MC903,
GS1500, and EB1213, respectively, i.e., no differences in the
ranking of the VDR ligands.
Functional activity of VDR agonists in HeLa and HaCaT
cells In order to test the functionality of 1a,25(OH)2D3 and
the three selected analogs, classical mammalian-one-hybrid assays
were performed in HeLa human cervix carcinoma cells that
were transiently transfected with an expression vector for a
fusion protein containing the DBD of the yeast transcription
factor GAL4 and the LBD of the VDR together with a
reporter gene construct containing a GAL4 binding site-driven
luciferase gene (Fig 5). The stimulation of the cells with graded
ligand concentrations provided a 25±35-fold induction of
reporter gene activity with EC50 values of 1.0 nM for
1a,25(OH)2D3, 0.1 nM for MC903, 0.11 nM for GS1500,
and 0.14 nM for EB1213. This indicates that the in vitro
sensitivity of the three analogs for the stabilization of VDR-
RXR-VDRE complexes (Figs 2 and 3) translates well to their
sensitivity in HeLa cells. In contrast, the natural hormone
appears to be approximately 10 times less sensitive in living cells
than in vitro.
Figure 6. Agonistic effects of 1a,25(OH)2D3
and its analogs in HaCaT cells. Luciferase
reporter gene assays were performed with extracts
from HaCaT cells that were transiently transfected
with a reporter gene construct-driven by three
copies of the GAL4 binding site and an expression
vector for a GAL4DBDVDRLBD fusion protein (A)
or with a luciferase reporter gene construct driven
by four copies of the rat ANF DR3-type VDRE
together with the expression vectors for VDR and
RXR (B) as schematically depicted above the
respective ®gures. The cells were treated for 16 h
with graded concentrations of 1a,25(OH)2D3 or
its analogs. Stimulation of luciferase activity was
calculated in comparison with solvent-induced
controls. Data points represent the mean of
triplicates and the bars indicate SD. The EC50
values for stimulation of VDR-driven gene
activity were determined from the respective
dose±response curves.
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The functional analysis of 1a,25(OH)2D3 and its analogs was
extended to HaCaT immortalized human keratinocytes as a
representative 1a,25(OH)2D3 target tissue. Mammalian-one-hy-
brid assays (Fig 6A) as well as traditional reporter gene assays
(Fig 6B), that used overexpressed VDR and RXR proteins and a
DR3-type VDRE-driven luciferase gene, were performed in this
cell line. Interestingly, the mammalian-one-hybrid assay (Fig 6A)
provided for all four ligands more than 100-fold induction of gene
activity, whereas the traditional assay (Fig 6B) only showed an
inducibility of 25-fold. Both types of reporter gene assays provided
for GS1500 and EB1213 EC50 values of 0.2±0.31 nM, i.e., values
that are very comparable with that obtained in HeLa cells (Fig 5).
This demonstrates that mammalian-one-hybrid assays are as
sensitive as traditional reporter gene assays. Moreover, the EC50
values that were obtained in both assays for 1a,25(OH)2D3 (1.1 and
2.8 nM) are in accordance with the results from HeLa cells
(1.0 nM, see Fig 5). In contrast, in HaCaT cells the sensitivity of
MC903 for activation of gene activity (EC50 values of 1.0 and
2.1 nM) was found to be 10±21-fold lower than in HeLa cells
(Fig 5).
DISCUSSION
The nuclear receptor superfamily contains a series of transcription
factors that are of high impact because they can be speci®cally
regulated in their activity by small lipophilic compounds of natural
or synthetic origin. The protein±DNA complex of nuclear receptor
and its speci®c response element can be considered as a molecular
switch for those genes that contain such a response element in their
promoter region. The VDR appears to be an ideal member of the
nuclear receptor superfamily, as apart from hypercalcemia no
signi®cant side-effects of its speci®c natural ligand, 1a,25(OH)2D3,
are known. This makes prevention of hypercalcemia a primary
target for the development of therapeutically important VDR
agonists. In this study, the molecular action of the natural hormone
was compared with that of three analogs that had been identi®ed by
biologic screenings to be low calcemic. Interestingly, on the level
of the activation of RXR- and DNA-complexed VDR, i.e., on the
level of the molecular switch, the sensitivity of all three analogs
(EC50 values of approximately 0.2 nM) was found to be not
signi®cantly different to that of 1a,25(OH)2D3 (Table I). This
identity was observed by two different methods, DNA-dependent
limited protease digestion assays and ligand-dependent gel shift
assays that appear to be very accurate tools for an in vitro evaluation
of nuclear receptor±DNA±ligand interactions. Similar results have
been obtained recently with other potent (but higher calcemic)
1a,25(OH)2D3 analogs, such as 20-epi-1a,25(OH)2D3, 20-
methyl-1a,25(OH)2D3 and an analog with two side chains,
referred to as Gemini (Herdick et al, 2000a). In that report, in
addition to the above-mentioned methods, supershifts with
coactivator proteins and gel shift clipping assays were used, but in
all cases the EC50 value for the activation of the VDR by any of
these ligands was found to be approximately 0.1 nM (Herdick et al,
2000a). This indicates that there appears to be a threshold of VDR
activation of 0.1±0.2 nM that even optimized synthetic VDR
agonists may not be able to exceed. This means that there is
probably no synthetic VDR agonists having an af®nity for the
VDR that is signi®cantly higher than that of the natural hormone.
This observation is supported by traditional ligand binding assays
(Binderup et al, 1994; Bouillon et al, 1995; van den Bemd et al,
1995).
Interestingly, the 1a,25(OH)2D3 analogs GS1500 and EB1213
showed the same EC50 values in the functional assays in HeLa and
HaCaT cells as in the in vitro assays (approximately 0.2 nM). This
indicates that the in vitro assays represent well the ligand sensitivity
of the VDR in living cells and in turn suggests that both analogs are
not signi®cantly metabolized or absorbed by cellular or serum
proteins. This conclusion appears to hold true for MC903 in HeLa
cells, but not in HaCaT cells, where the EC50 value was found to
be 22-fold higher. The reason for this difference is yet unknown
and apparently not related to a fast metabolism of MC903 in
HaCaT cells, in which the analog was shown to be rather stable
(Lùgsted Nielsen and Kissmeyer, unpublished results). In contrast,
1a,25(OH)2D3 showed higher EC50 values in the functional assays
in HeLa and HaCaT cells compared with the in vitro assays. The
functional assays are performed in the presence of serum and
thereby also vitamin D binding protein. Therefore, it is likely that
the binding of 1a,25(OH)2D3 to vitamin D binding protein has
suppressed the free entry 1a,25(OH)2D3 into the cells and thereby
increased the EC50 value (Vanham et al, 1988). As most
1a,25(OH)2D3 analogs have a reduced af®nity for vitamin D
binding protein compared with the natural hormone (Kissmeyer
et al, 1995) the same difference in activity between functional and
in vitro assays is, as observed, not expected.
On ®rst glance, the functionality of MC903, GS1500, and
EB1213 in vitro and in HeLa cells appears to be identical (Table I);
however, in proliferation assays in HaCaT cells GS1500 and
EB1213 are known to be more potent than MC903 and
1a,25(OH)2D3 (Mùrk Hansen et al, 1996). This may be due to
important differences in stabilizing either the VDR in solution or
Table I. Comparison of the four tested VDR ligandsa
VDR ligand 1a,25(OH)2D3 MC903 GS1500 EB1213
DNA-dependent stabilization
of VDR conformations (t1/2 in min)
660 438 1175 2717
DNA-dependent stabilization
of c1LPD (t1/2 in min)
472 260 1260 3375
DNA-independent stabilization
of c1LPD (EC50 value in nM)
1.5 1.2 10 1.1
DNA-dependent stabilization
of c1LPD (EC50 value in nM)
0.3 0.3 0.2 0.26
VDR-RXR-VDRE complex
formation (EC50 value in nM)
0.2 0.095 0.4 0.17
Functional activity of VDRLBD
in HeLa cells (EC50 value in nM)
1.0 0.1 0.11 0.14
Functional activity of VDRLBD
in HaCaT cells (EC50 value in nM)
1.1 2.1 0.22 0.31
Functional activity of VDR-RXR
in HaCaT cells (EC50 value in nM)
2.8 1.0 0.28 0.2
Anti-proliferative activity in
HaCaT cells (IC50 value in nM)
50 32 0.11 0.28
aAnti-proliferative data from Mùrk Hansen et al (1996).
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VDR-RXR-VDRE complexes over time. Compared with the
three other tested VDR agonists, GS1500 showed a clear
preference for DNA-bound VDR-RXR complexes (Table I). A
selectivity for DNA-bound VDR-RXR heterodimers means that
DNA-independent actions of the VDR, such as the inhibition of
IL-2 gene expression via the prevention of DNA binding of the
transcription factor NF-AT (Alroy et al, 1995), will not be
stimulated (or only at clearly higher concentrations) by the
respective ligand. Moreover, GS1500 stabilized DNA-bound
VDR-RXR complexes nearly twice as long as 1a,25(OH)2D3,
whereas MC903 kept the complex stable only for a shorter time
period than the natural hormone; however, EB1213 appears to be
most potent as it stabilizes VDR-RXR-VDRE complexes more
than four times longer than 1a,25(OH)2D3. An increased ligand-
dependent stabilization of VDR-RXR-VDRE complexes would
then result in longer-lasting effects of the respective ligand on gene
activation.
In conclusion, the molecular evaluation of the analogs MC903,
GS1500, and EB1213 in comparison with the natural hormone has
indicated that they are all potent VDR agonists that show a very
similar sensitivity in stabilizing the molecular switches of nuclear
1a,25(OH)2D3 signaling, i.e., DNA-bound VDR-RXR hetero-
dimers. Individual properties of the compounds, however, could
also be identi®ed, of which the skin cell-speci®c reduced sensitivity
of MC903, the DNA selectivity of GS1500 and the long-lasting
stabilization of VDR-RXR-VDRE complexes by EB1213 are the
most remarkable.
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